F m Investments LLC has boosted its investment in Eli Lilly and Company (NYSE: LLY) by 4.1% during the third quarter of 2023. This strategic move means the firm now owns 38,388 shares of Eli Lilly, following the acquisition of an additional 1,528 shares. As of the end of September 2023, the total value of F m Investments’ holdings in Eli Lilly stood at approximately $29.29 million, representing around 1.1% of its overall portfolio.
Several other institutional investors have also adjusted their positions in Eli Lilly recently. FORA Capital LLC established a new stake valued at approximately $1.24 million, while FreeGulliver LLC acquired shares worth around $354,000. Game Creek Capital LP notably expanded its holdings by 222.8%, now owning 7,425 shares valued at about $5.67 million. Glenmede Investment Management LP increased its position by 1.1%, owning 314,370 shares valued at approximately $239.86 million. Boston Partners also entered the market with a new stake valued at about $682,000. Currently, institutional investors and hedge funds hold roughly 82.53% of Eli Lilly’s shares.
Analysts Update Price Targets for Eli Lilly
Recent reports from equity research analysts have influenced the outlook on Eli Lilly’s stock. Royal Bank of Canada started coverage with an “outperform” rating, proposing a target price of $1,250.00 for the stock. Guggenheim raised its target from $1,161.00 to $1,168.00, maintaining a “buy” rating. UBS Group reiterated a “buy” rating on February 2, 2024, while CICC Research lifted its price objective to $1,107.00 with a “neutral” rating. Meanwhile, Daiwa Securities Group increased its target from $1,230.00 to $1,250.00. Overall, the consensus rating stands at “Moderate Buy,” with a target price averaging $1,229.59.
Recent Developments at Eli Lilly
Eli Lilly has been active in expanding its operations and product offerings, particularly in the growing GLP-1 market. The company plans to invest $3 billion over the next decade in China, aiming to secure supply and enhance market share. This ambitious strategy is expected to create a clear revenue runway against local competitors.
In terms of product access, the expansion of Medicare to include Eli Lilly’s Zepbound and Mounjaro is expected to broaden the patient base significantly. This development addresses previous barriers to volume growth for Eli Lilly’s injectable GLP-1 products.
Additionally, Eli Lilly is making strides with its Employer Connect initiative, which seeks to improve employer coverage and reduce out-of-pocket costs for Zepbound. Enhanced uptake from employers could further boost sales. The company is also progressing in its clinical pipeline, advancing a Phase-1 study of eloralintide in high-risk kidney patients, which may lead to expanded indications beyond obesity and diabetes.
Despite these positive developments, concerns have emerged regarding safety, particularly with a warning about an unknown impurity found in compounded tirzepatide mixed with vitamin B12. Such issues may raise regulatory scrutiny and could affect market perception. Analysts have noted a decline in trading momentum since November 2023, suggesting that high valuations could be at risk should investor sentiment shift.
Eli Lilly’s stock opened at $985.10 on February 2, 2024. The company has a 50-day moving average of $1,037.28 and a 200-day moving average of $949.30. Over the past year, the stock has fluctuated between a low of $623.78 and a high of $1,133.95. With a market capitalization of approximately $930.74 billion and a price-to-earnings ratio of 42.92, Eli Lilly continues to be a significant player in the pharmaceutical sector.
On February 4, 2024, Eli Lilly reported quarterly earnings of $7.54 per share, surpassing analysts’ estimates of $7.48 by $0.06. The company achieved a net margin of 31.66% and a return on equity of 102.94%, with revenue reaching $19.29 billion, significantly exceeding the consensus estimate of $17.85 billion. Year-over-year, revenue increased by 42.6%. Eli Lilly has also projected earnings per share for fiscal year 2026 to be between $33.50 and $35.00.
Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company is a global pharmaceutical leader focused on developing and commercializing a wide range of medications and therapies for patients worldwide. The company operates across North America, Europe, and Asia, serving both developed and emerging markets under the leadership of President and Chief Executive Officer David A. Ricks.
